See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is a chemotherapy drug that is used to treat small cell lung cancer and is administered through intravenous injection [2]. According to the drug's label, there is not enough information available about the drug's effects on breastfeeding mothers and their infants. Therefore, it is not recommended for breastfeeding mothers to use this drug [3].

The drug's label also warns against using the drug during pregnancy, as it may cause harm to the fetus. Women of childbearing age are advised to use effective contraception during treatment with lurbinectedin [3].

The side effects of lurbinectedin include nausea, vomiting, fatigue, decreased appetite, and low white blood cell count [2]. These side effects can be severe and may require medical attention.

In conclusion, there is not enough information available about the effects of lurbinectedin on breastfeeding mothers and their infants. Therefore, it is not recommended for breastfeeding mothers to use this drug. Women of childbearing age are advised to use effective contraception during treatment with lurbinectedin. The drug may cause side effects such as nausea, vomiting, fatigue, decreased appetite, and low white blood cell count.

Sources:
[2] DrugPatentWatch. Lurbinectedin. https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN. Accessed 15 Feb. 2021.

[3] Mayo Clinic. Lurbinectedin (Intravenous Route): Side Effects. https://www.mayoclinic.org/drugs-supplements/lurbinectedin-intravenous-route/side-effects/drg-20490804?p=1. Accessed 15 Feb. 2021.

[4] FDA. Lurbinectedin. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf. Accessed 15 Feb. 2021.